nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC4—Sorafenib—liver cancer	0.378	1	CbGbCtD
Alprostadil—Balanitis—Epirubicin—liver cancer	0.00828	0.027	CcSEcCtD
Alprostadil—Testicular disorder—Epirubicin—liver cancer	0.00783	0.0255	CcSEcCtD
Alprostadil—Balanitis—Doxorubicin—liver cancer	0.00766	0.0249	CcSEcCtD
Alprostadil—Testicular disorder—Doxorubicin—liver cancer	0.00725	0.0236	CcSEcCtD
Alprostadil—Dinoprost Tromethamine—HPGDS—liver cancer	0.00667	0.469	CrCbGaD
Alprostadil—Cerebral haemorrhage—Sorafenib—liver cancer	0.00664	0.0216	CcSEcCtD
Alprostadil—Haematoma—Sorafenib—liver cancer	0.00585	0.019	CcSEcCtD
Alprostadil—Respiratory distress—Sorafenib—liver cancer	0.00579	0.0188	CcSEcCtD
Alprostadil—Dinoprostone—HPGDS—liver cancer	0.00513	0.36	CrCbGaD
Alprostadil—Injection site haemorrhage—Epirubicin—liver cancer	0.00505	0.0164	CcSEcCtD
Alprostadil—Injection site haemorrhage—Doxorubicin—liver cancer	0.00467	0.0152	CcSEcCtD
Alprostadil—Warmth—Epirubicin—liver cancer	0.00427	0.0139	CcSEcCtD
Alprostadil—Injection site inflammation—Epirubicin—liver cancer	0.00407	0.0133	CcSEcCtD
Alprostadil—Warmth—Doxorubicin—liver cancer	0.00395	0.0129	CcSEcCtD
Alprostadil—Anuria—Epirubicin—liver cancer	0.00389	0.0127	CcSEcCtD
Alprostadil—Injection site inflammation—Doxorubicin—liver cancer	0.00377	0.0123	CcSEcCtD
Alprostadil—Supraventricular extrasystoles—Epirubicin—liver cancer	0.00365	0.0119	CcSEcCtD
Alprostadil—Anuria—Doxorubicin—liver cancer	0.0036	0.0117	CcSEcCtD
Alprostadil—Influenza like illness—Sorafenib—liver cancer	0.00357	0.0116	CcSEcCtD
Alprostadil—Hypochromic anaemia—Epirubicin—liver cancer	0.0035	0.0114	CcSEcCtD
Alprostadil—Supraventricular extrasystoles—Doxorubicin—liver cancer	0.00337	0.011	CcSEcCtD
Alprostadil—Tooth abscess—Epirubicin—liver cancer	0.00325	0.0106	CcSEcCtD
Alprostadil—Hypochromic anaemia—Doxorubicin—liver cancer	0.00324	0.0106	CcSEcCtD
Alprostadil—Prostatic disorder—Epirubicin—liver cancer	0.0032	0.0104	CcSEcCtD
Alprostadil—Tooth abscess—Doxorubicin—liver cancer	0.00301	0.0098	CcSEcCtD
Alprostadil—Prostatic disorder—Doxorubicin—liver cancer	0.00296	0.00963	CcSEcCtD
Alprostadil—Cardiac failure congestive—Sorafenib—liver cancer	0.00294	0.00958	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Epirubicin—liver cancer	0.00277	0.00902	CcSEcCtD
Alprostadil—Pneumothorax—Epirubicin—liver cancer	0.00273	0.00889	CcSEcCtD
Alprostadil—Pain in extremity—Sorafenib—liver cancer	0.00267	0.00869	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Doxorubicin—liver cancer	0.00256	0.00835	CcSEcCtD
Alprostadil—Pneumothorax—Doxorubicin—liver cancer	0.00253	0.00823	CcSEcCtD
Alprostadil—Local reaction—Epirubicin—liver cancer	0.00245	0.00799	CcSEcCtD
Alprostadil—Ethanolamine Oleate—CYP2E1—liver cancer	0.00243	0.171	CrCbGaD
Alprostadil—Hypokalaemia—Sorafenib—liver cancer	0.00243	0.00791	CcSEcCtD
Alprostadil—Body temperature decreased—Epirubicin—liver cancer	0.00242	0.00789	CcSEcCtD
Alprostadil—Hypothermia—Epirubicin—liver cancer	0.00242	0.00789	CcSEcCtD
Alprostadil—Local reaction—Doxorubicin—liver cancer	0.00227	0.00739	CcSEcCtD
Alprostadil—Body temperature decreased—Doxorubicin—liver cancer	0.00224	0.0073	CcSEcCtD
Alprostadil—Hypothermia—Doxorubicin—liver cancer	0.00224	0.0073	CcSEcCtD
Alprostadil—Pelvic pain—Epirubicin—liver cancer	0.00223	0.00727	CcSEcCtD
Alprostadil—Serum creatinine increased—Epirubicin—liver cancer	0.00221	0.00719	CcSEcCtD
Alprostadil—Pelvic pain—Doxorubicin—liver cancer	0.00207	0.00673	CcSEcCtD
Alprostadil—Serum creatinine increased—Doxorubicin—liver cancer	0.00204	0.00666	CcSEcCtD
Alprostadil—Acute coronary syndrome—Sorafenib—liver cancer	0.00203	0.0066	CcSEcCtD
Alprostadil—Renal failure—Sorafenib—liver cancer	0.00202	0.00658	CcSEcCtD
Alprostadil—Myocardial infarction—Sorafenib—liver cancer	0.00202	0.00656	CcSEcCtD
Alprostadil—Redness—Epirubicin—liver cancer	0.00201	0.00655	CcSEcCtD
Alprostadil—Burning sensation—Epirubicin—liver cancer	0.00196	0.00637	CcSEcCtD
Alprostadil—Redness—Doxorubicin—liver cancer	0.00186	0.00606	CcSEcCtD
Alprostadil—Haemoglobin—Sorafenib—liver cancer	0.00186	0.00604	CcSEcCtD
Alprostadil—Haemorrhage—Sorafenib—liver cancer	0.00185	0.00601	CcSEcCtD
Alprostadil—Urethral disorder—Sorafenib—liver cancer	0.00181	0.00589	CcSEcCtD
Alprostadil—Burning sensation—Doxorubicin—liver cancer	0.00181	0.00589	CcSEcCtD
Alprostadil—Fungal infection—Epirubicin—liver cancer	0.00176	0.00573	CcSEcCtD
Alprostadil—Feeling hot—Epirubicin—liver cancer	0.00173	0.00564	CcSEcCtD
Alprostadil—Flushing—Sorafenib—liver cancer	0.00171	0.00558	CcSEcCtD
Alprostadil—Injection site pain—Epirubicin—liver cancer	0.00166	0.00542	CcSEcCtD
Alprostadil—Fungal infection—Doxorubicin—liver cancer	0.00163	0.0053	CcSEcCtD
Alprostadil—Erythema—Sorafenib—liver cancer	0.00161	0.00523	CcSEcCtD
Alprostadil—Feeling hot—Doxorubicin—liver cancer	0.0016	0.00522	CcSEcCtD
Alprostadil—Vasodilation—Epirubicin—liver cancer	0.00155	0.00504	CcSEcCtD
Alprostadil—Vasodilation procedure—Epirubicin—liver cancer	0.00155	0.00504	CcSEcCtD
Alprostadil—Muscle spasms—Sorafenib—liver cancer	0.00155	0.00503	CcSEcCtD
Alprostadil—Injection site pain—Doxorubicin—liver cancer	0.00154	0.00501	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00149	0.00487	CcSEcCtD
Alprostadil—Anaemia—Sorafenib—liver cancer	0.00149	0.00484	CcSEcCtD
Alprostadil—Syncope—Sorafenib—liver cancer	0.00144	0.00469	CcSEcCtD
Alprostadil—Vasodilation procedure—Doxorubicin—liver cancer	0.00143	0.00466	CcSEcCtD
Alprostadil—Vasodilation—Doxorubicin—liver cancer	0.00143	0.00466	CcSEcCtD
Alprostadil—Loss of consciousness—Sorafenib—liver cancer	0.00141	0.0046	CcSEcCtD
Alprostadil—Cough—Sorafenib—liver cancer	0.0014	0.00457	CcSEcCtD
Alprostadil—Hypertension—Sorafenib—liver cancer	0.00139	0.00452	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00138	0.0045	CcSEcCtD
Alprostadil—Injection site reaction—Epirubicin—liver cancer	0.00135	0.0044	CcSEcCtD
Alprostadil—Dry mouth—Sorafenib—liver cancer	0.00134	0.00436	CcSEcCtD
Alprostadil—Hyperkalaemia—Epirubicin—liver cancer	0.00133	0.00435	CcSEcCtD
Alprostadil—Influenza like illness—Epirubicin—liver cancer	0.00132	0.0043	CcSEcCtD
Alprostadil—Infection—Sorafenib—liver cancer	0.0013	0.00424	CcSEcCtD
Alprostadil—Shock—Sorafenib—liver cancer	0.00129	0.0042	CcSEcCtD
Alprostadil—Thrombocytopenia—Sorafenib—liver cancer	0.00128	0.00418	CcSEcCtD
Alprostadil—Skin disorder—Sorafenib—liver cancer	0.00127	0.00415	CcSEcCtD
Alprostadil—Injection site reaction—Doxorubicin—liver cancer	0.00125	0.00407	CcSEcCtD
Alprostadil—Cramps of lower extremities—Epirubicin—liver cancer	0.00125	0.00406	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—liver cancer	0.00124	0.00402	CcSEcCtD
Alprostadil—Ecchymosis—Epirubicin—liver cancer	0.00123	0.004	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—liver cancer	0.00122	0.00398	CcSEcCtD
Alprostadil—Abnormal vision—Epirubicin—liver cancer	0.00119	0.00386	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—liver cancer	0.00118	0.00384	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—liver cancer	0.00115	0.00376	CcSEcCtD
Alprostadil—Dyspepsia—Sorafenib—liver cancer	0.00115	0.00376	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—liver cancer	0.00114	0.0037	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—liver cancer	0.00113	0.00369	CcSEcCtD
Alprostadil—Pain—Sorafenib—liver cancer	0.00112	0.00365	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—liver cancer	0.0011	0.00357	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—liver cancer	0.00109	0.00355	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—liver cancer	0.00109	0.00354	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—liver cancer	0.00105	0.00342	CcSEcCtD
Alprostadil—Abdominal pain—Sorafenib—liver cancer	0.00104	0.00338	CcSEcCtD
Alprostadil—Body temperature increased—Sorafenib—liver cancer	0.00104	0.00338	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—liver cancer	0.00101	0.00329	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—liver cancer	0.00101	0.00328	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—liver cancer	0.00101	0.00328	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—liver cancer	0.000986	0.00321	CcSEcCtD
Alprostadil—Asthenia—Sorafenib—liver cancer	0.000941	0.00306	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—liver cancer	0.000938	0.00305	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—liver cancer	0.000935	0.00304	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—liver cancer	0.000931	0.00303	CcSEcCtD
Alprostadil—Pruritus—Sorafenib—liver cancer	0.000928	0.00302	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—liver cancer	0.000924	0.00301	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—liver cancer	0.000913	0.00297	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—liver cancer	0.000898	0.00292	CcSEcCtD
Alprostadil—Diarrhoea—Sorafenib—liver cancer	0.000897	0.00292	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—liver cancer	0.000868	0.00283	CcSEcCtD
Alprostadil—Dizziness—Sorafenib—liver cancer	0.000867	0.00282	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—liver cancer	0.000855	0.00278	CcSEcCtD
Alprostadil—Influenza—Epirubicin—liver cancer	0.000852	0.00278	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—liver cancer	0.000831	0.0027	CcSEcCtD
Alprostadil—Rash—Sorafenib—liver cancer	0.000827	0.00269	CcSEcCtD
Alprostadil—Dermatitis—Sorafenib—liver cancer	0.000826	0.00269	CcSEcCtD
Alprostadil—Headache—Sorafenib—liver cancer	0.000822	0.00268	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—liver cancer	0.00082	0.00267	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—liver cancer	0.000792	0.00258	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—liver cancer	0.000789	0.00257	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—liver cancer	0.000788	0.00256	CcSEcCtD
Alprostadil—Nausea—Sorafenib—liver cancer	0.000779	0.00254	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—liver cancer	0.000769	0.0025	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—liver cancer	0.000759	0.00247	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—liver cancer	0.000747	0.00243	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—liver cancer	0.000739	0.00241	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000733	0.00239	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—liver cancer	0.000729	0.00237	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—liver cancer	0.000725	0.00236	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—liver cancer	0.000713	0.00232	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—liver cancer	0.000712	0.00232	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—liver cancer	0.000695	0.00226	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—liver cancer	0.000691	0.00225	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—liver cancer	0.000686	0.00223	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—liver cancer	0.000684	0.00223	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—liver cancer	0.000684	0.00223	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—liver cancer	0.000682	0.00222	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—liver cancer	0.000679	0.00221	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—liver cancer	0.000677	0.00221	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—liver cancer	0.000671	0.00218	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—liver cancer	0.000669	0.00218	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—liver cancer	0.00066	0.00215	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—liver cancer	0.000658	0.00214	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—liver cancer	0.000643	0.00209	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—liver cancer	0.000635	0.00207	CcSEcCtD
Alprostadil—Flushing—Epirubicin—liver cancer	0.000633	0.00206	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—liver cancer	0.000633	0.00206	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—liver cancer	0.000631	0.00206	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—liver cancer	0.000628	0.00205	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—liver cancer	0.000627	0.00204	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—liver cancer	0.000619	0.00202	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—liver cancer	0.000608	0.00198	CcSEcCtD
Alprostadil—Erythema—Epirubicin—liver cancer	0.000594	0.00193	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—liver cancer	0.000586	0.00191	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—liver cancer	0.000577	0.00188	CcSEcCtD
Alprostadil—Back pain—Epirubicin—liver cancer	0.000575	0.00187	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—liver cancer	0.000571	0.00186	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—liver cancer	0.00055	0.00179	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—liver cancer	0.000549	0.00179	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—liver cancer	0.000534	0.00174	CcSEcCtD
Alprostadil—Syncope—Epirubicin—liver cancer	0.000533	0.00173	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—liver cancer	0.000532	0.00173	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—liver cancer	0.000528	0.00172	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—liver cancer	0.000522	0.0017	CcSEcCtD
Alprostadil—Cough—Epirubicin—liver cancer	0.000518	0.00169	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—liver cancer	0.000515	0.00168	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—liver cancer	0.000513	0.00167	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—liver cancer	0.000508	0.00165	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—liver cancer	0.0005	0.00163	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—liver cancer	0.000495	0.00161	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—liver cancer	0.000493	0.0016	CcSEcCtD
Alprostadil—Oedema—Epirubicin—liver cancer	0.000485	0.00158	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—liver cancer	0.000483	0.00157	CcSEcCtD
Alprostadil—Infection—Epirubicin—liver cancer	0.000482	0.00157	CcSEcCtD
Alprostadil—Cough—Doxorubicin—liver cancer	0.00048	0.00156	CcSEcCtD
Alprostadil—Shock—Epirubicin—liver cancer	0.000477	0.00155	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—liver cancer	0.000476	0.00155	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—liver cancer	0.000475	0.00155	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—liver cancer	0.000475	0.00155	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—liver cancer	0.000473	0.00154	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—liver cancer	0.000471	0.00153	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—liver cancer	0.000469	0.00153	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—liver cancer	0.000462	0.00151	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—liver cancer	0.000458	0.00149	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—liver cancer	0.000453	0.00147	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—liver cancer	0.000449	0.00146	CcSEcCtD
Alprostadil—Infection—Doxorubicin—liver cancer	0.000446	0.00145	CcSEcCtD
Alprostadil—Shock—Doxorubicin—liver cancer	0.000441	0.00144	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—liver cancer	0.000439	0.00143	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—liver cancer	0.000438	0.00143	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—liver cancer	0.000436	0.00142	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—liver cancer	0.000434	0.00141	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—liver cancer	0.000427	0.00139	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—liver cancer	0.000419	0.00136	CcSEcCtD
Alprostadil—Pain—Epirubicin—liver cancer	0.000415	0.00135	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—liver cancer	0.000399	0.0013	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—liver cancer	0.000395	0.00129	CcSEcCtD
Alprostadil—Pain—Doxorubicin—liver cancer	0.000384	0.00125	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—liver cancer	0.000383	0.00125	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—liver cancer	0.000383	0.00125	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—liver cancer	0.00037	0.0012	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—liver cancer	0.000355	0.00115	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—liver cancer	0.000355	0.00115	CcSEcCtD
Alprostadil—Asthenia—Epirubicin—liver cancer	0.000348	0.00113	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—liver cancer	0.000343	0.00112	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—liver cancer	0.000332	0.00108	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—liver cancer	0.000322	0.00105	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—liver cancer	0.000321	0.00104	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—liver cancer	0.000317	0.00103	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—liver cancer	0.000307	0.000999	CcSEcCtD
Alprostadil—Rash—Epirubicin—liver cancer	0.000306	0.000995	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—liver cancer	0.000305	0.000994	CcSEcCtD
Alprostadil—Headache—Epirubicin—liver cancer	0.000304	0.000989	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—liver cancer	0.000297	0.000966	CcSEcCtD
Alprostadil—Nausea—Epirubicin—liver cancer	0.000288	0.000938	CcSEcCtD
Alprostadil—Rash—Doxorubicin—liver cancer	0.000283	0.000921	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—liver cancer	0.000283	0.00092	CcSEcCtD
Alprostadil—Headache—Doxorubicin—liver cancer	0.000281	0.000915	CcSEcCtD
Alprostadil—Nausea—Doxorubicin—liver cancer	0.000266	0.000868	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—HGF—liver cancer	0.000163	0.000543	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CSF2—liver cancer	0.000162	0.000537	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GOT2—liver cancer	0.00016	0.000532	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—RAF1—liver cancer	0.00016	0.000531	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CB—liver cancer	0.000156	0.000518	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CSF2—liver cancer	0.000156	0.000517	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CSF2—liver cancer	0.000156	0.000517	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HPGDS—liver cancer	0.000155	0.000514	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PRKCE—liver cancer	0.000154	0.000511	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CD—liver cancer	0.000152	0.000505	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000152	0.000505	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CB—liver cancer	0.000146	0.000485	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF2—liver cancer	0.000146	0.000484	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL2—liver cancer	0.000143	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADAM17—liver cancer	0.000143	0.000474	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADAM17—liver cancer	0.000143	0.000474	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—liver cancer	0.000141	0.000468	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GOT1—liver cancer	0.000138	0.00046	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSMD10—liver cancer	0.000138	0.000458	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSMA4—liver cancer	0.000138	0.000458	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ALB—liver cancer	0.000138	0.000457	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CSF2—liver cancer	0.000136	0.000452	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—RAF1—liver cancer	0.000136	0.000451	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—F2—liver cancer	0.000134	0.000447	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—F2—liver cancer	0.000134	0.000447	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GOT2—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSMA4—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSMD10—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSMA4—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSMD10—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—H2AFX—liver cancer	0.000134	0.000446	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL2—liver cancer	0.000134	0.000445	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CB—liver cancer	0.000132	0.00044	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—liver cancer	0.000131	0.000437	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK14—liver cancer	0.000131	0.000435	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—liver cancer	0.000129	0.000429	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CG—liver cancer	0.000129	0.000428	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CG—liver cancer	0.000129	0.000428	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PRKCE—liver cancer	0.000128	0.000424	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—F2—liver cancer	0.000127	0.000421	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP2E1—liver cancer	0.000126	0.000419	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—RAF1—liver cancer	0.000124	0.000414	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PPARA—liver cancer	0.000123	0.000408	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—F2—liver cancer	0.000122	0.000406	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—F2—liver cancer	0.000122	0.000406	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—liver cancer	0.000122	0.000405	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL2—liver cancer	0.000122	0.000405	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CG—liver cancer	0.000121	0.000403	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—liver cancer	0.000121	0.000403	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—RAF1—liver cancer	0.000119	0.000395	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYCS—liver cancer	0.000118	0.000392	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CG—liver cancer	0.000117	0.000388	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CG—liver cancer	0.000117	0.000388	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GOT1—liver cancer	0.000116	0.000385	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GGT1—liver cancer	0.000116	0.000385	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CD—liver cancer	0.000113	0.000376	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CD—liver cancer	0.000113	0.000376	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—liver cancer	0.000112	0.000371	CbGpPWpGaD
Alprostadil—ABCC5—Disease—H2AFX—liver cancer	0.000111	0.00037	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KDR—liver cancer	0.000111	0.000369	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK14—liver cancer	0.00011	0.000366	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	0.00011	0.000365	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—liver cancer	0.000108	0.000359	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—F2—liver cancer	0.000107	0.000355	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CD—liver cancer	0.000107	0.000355	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—liver cancer	0.000105	0.000351	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—liver cancer	0.000105	0.00035	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTP1—liver cancer	0.000104	0.000346	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCE—liver cancer	0.000104	0.000345	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCE—liver cancer	0.000104	0.000345	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—liver cancer	0.000103	0.000344	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CD—liver cancer	0.000103	0.000341	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CD—liver cancer	0.000103	0.000341	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—liver cancer	0.000103	0.000341	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—liver cancer	0.000102	0.00034	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APC—liver cancer	0.000102	0.00034	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—liver cancer	0.000101	0.000335	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—liver cancer	0.000101	0.000334	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CB—liver cancer	9.86e-05	0.000328	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CB—liver cancer	9.86e-05	0.000328	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF2—liver cancer	9.84e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF2—liver cancer	9.84e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BRAF—liver cancer	9.6e-05	0.000319	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—liver cancer	9.56e-05	0.000318	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RAF1—liver cancer	9.52e-05	0.000317	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—liver cancer	9.51e-05	0.000316	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—liver cancer	9.3e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—liver cancer	9.2e-05	0.000306	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CSF2—liver cancer	9.19e-05	0.000305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CSF2—liver cancer	9.19e-05	0.000305	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RAF1—liver cancer	9.17e-05	0.000305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RAF1—liver cancer	9.17e-05	0.000305	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—liver cancer	9.11e-05	0.000303	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1A1—liver cancer	9.06e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—H2AFX—liver cancer	9.06e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—H2AFX—liver cancer	9.06e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—liver cancer	9.05e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—liver cancer	9.05e-05	0.000301	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—liver cancer	8.98e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—liver cancer	8.98e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—liver cancer	8.95e-05	0.000298	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—liver cancer	8.95e-05	0.000298	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—liver cancer	8.89e-05	0.000296	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—liver cancer	8.88e-05	0.000295	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—liver cancer	8.8e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—liver cancer	8.79e-05	0.000292	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—liver cancer	8.54e-05	0.000284	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APC—liver cancer	8.47e-05	0.000282	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—liver cancer	8.45e-05	0.000281	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARA—liver cancer	8.29e-05	0.000275	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—RAF1—liver cancer	8.24e-05	0.000274	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—liver cancer	8.22e-05	0.000273	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—liver cancer	8.22e-05	0.000273	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—liver cancer	8.19e-05	0.000272	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—liver cancer	8.19e-05	0.000272	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—liver cancer	8.08e-05	0.000269	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RAF1—liver cancer	8.02e-05	0.000267	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—liver cancer	7.96e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—liver cancer	7.83e-05	0.00026	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MTOR—liver cancer	7.83e-05	0.00026	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—liver cancer	7.77e-05	0.000258	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KDR—liver cancer	7.49e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KDR—liver cancer	7.49e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—liver cancer	7.47e-05	0.000248	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—liver cancer	7.45e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK14—liver cancer	7.44e-05	0.000247	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK14—liver cancer	7.44e-05	0.000247	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—liver cancer	7.37e-05	0.000245	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1B—liver cancer	7.35e-05	0.000244	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—liver cancer	7.3e-05	0.000243	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—liver cancer	7.3e-05	0.000243	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—liver cancer	7.27e-05	0.000242	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—liver cancer	7.25e-05	0.000241	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—F2—liver cancer	7.21e-05	0.00024	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—F2—liver cancer	7.21e-05	0.00024	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—liver cancer	7.2e-05	0.000239	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—liver cancer	7.19e-05	0.000239	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—liver cancer	7.15e-05	0.000238	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—liver cancer	7.1e-05	0.000236	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—liver cancer	7.01e-05	0.000233	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—JUN—liver cancer	6.99e-05	0.000232	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNB1—liver cancer	6.94e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APC—liver cancer	6.9e-05	0.000229	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—liver cancer	6.9e-05	0.000229	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APC—liver cancer	6.9e-05	0.000229	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—liver cancer	6.9e-05	0.000229	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—liver cancer	6.85e-05	0.000228	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—liver cancer	6.8e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1A—liver cancer	6.78e-05	0.000225	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—liver cancer	6.66e-05	0.000221	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RAF1—liver cancer	6.65e-05	0.000221	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK8—liver cancer	6.62e-05	0.00022	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—liver cancer	6.6e-05	0.000219	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—liver cancer	6.49e-05	0.000216	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTOR—liver cancer	6.49e-05	0.000216	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—liver cancer	6.49e-05	0.000216	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—liver cancer	6.49e-05	0.000216	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—liver cancer	6.24e-05	0.000207	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—liver cancer	6.17e-05	0.000205	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—liver cancer	6.16e-05	0.000205	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—liver cancer	6.11e-05	0.000203	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1B—liver cancer	6.09e-05	0.000203	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—liver cancer	6.07e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—liver cancer	6.07e-05	0.000202	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—liver cancer	6.05e-05	0.000201	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—liver cancer	6.01e-05	0.0002	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—liver cancer	6.01e-05	0.0002	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—liver cancer	6e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—liver cancer	6e-05	0.000199	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—liver cancer	5.94e-05	0.000197	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—liver cancer	5.94e-05	0.000197	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CTNNB1—liver cancer	5.76e-05	0.000191	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—liver cancer	5.67e-05	0.000188	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1A—liver cancer	5.62e-05	0.000187	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—liver cancer	5.62e-05	0.000187	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—liver cancer	5.61e-05	0.000186	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—liver cancer	5.48e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—liver cancer	5.46e-05	0.000181	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—liver cancer	5.46e-05	0.000181	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—liver cancer	5.44e-05	0.000181	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAF1—liver cancer	5.42e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAF1—liver cancer	5.42e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—liver cancer	5.29e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—liver cancer	5.29e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MTOR—liver cancer	5.29e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MTOR—liver cancer	5.29e-05	0.000176	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—liver cancer	5.24e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—liver cancer	5.19e-05	0.000173	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—liver cancer	5.05e-05	0.000168	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—liver cancer	5.05e-05	0.000168	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—liver cancer	5.02e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1B—liver cancer	4.96e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1B—liver cancer	4.96e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—liver cancer	4.91e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—liver cancer	4.91e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—liver cancer	4.86e-05	0.000162	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—liver cancer	4.86e-05	0.000162	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—liver cancer	4.86e-05	0.000161	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—liver cancer	4.86e-05	0.000161	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—liver cancer	4.83e-05	0.000161	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—liver cancer	4.83e-05	0.000161	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—liver cancer	4.77e-05	0.000159	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—liver cancer	4.73e-05	0.000157	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—liver cancer	4.73e-05	0.000157	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—JUN—liver cancer	4.72e-05	0.000157	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—JUN—liver cancer	4.72e-05	0.000157	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNB1—liver cancer	4.69e-05	0.000156	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNB1—liver cancer	4.69e-05	0.000156	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—liver cancer	4.66e-05	0.000155	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—liver cancer	4.65e-05	0.000155	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—liver cancer	4.63e-05	0.000154	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—liver cancer	4.62e-05	0.000153	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—liver cancer	4.6e-05	0.000153	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—liver cancer	4.6e-05	0.000153	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1A—liver cancer	4.58e-05	0.000152	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1A—liver cancer	4.58e-05	0.000152	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK8—liver cancer	4.47e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK8—liver cancer	4.47e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—liver cancer	4.46e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—liver cancer	4.46e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—liver cancer	4.41e-05	0.000147	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—liver cancer	4.31e-05	0.000143	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—liver cancer	4.22e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—liver cancer	4.13e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—liver cancer	4.13e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—liver cancer	4.09e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—liver cancer	4.09e-05	0.000136	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—liver cancer	3.96e-05	0.000132	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—liver cancer	3.9e-05	0.00013	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—liver cancer	3.8e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—liver cancer	3.8e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—liver cancer	3.79e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—liver cancer	3.79e-05	0.000126	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—liver cancer	3.66e-05	0.000122	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—liver cancer	3.51e-05	0.000117	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—liver cancer	3.51e-05	0.000117	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—liver cancer	3.5e-05	0.000117	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—liver cancer	3.31e-05	0.00011	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—liver cancer	3.23e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—liver cancer	3.22e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—liver cancer	3.22e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—liver cancer	3.12e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—liver cancer	3.12e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—liver cancer	2.98e-05	9.91e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—liver cancer	2.98e-05	9.91e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—liver cancer	2.85e-05	9.49e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—liver cancer	2.85e-05	9.49e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—liver cancer	2.71e-05	9e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—liver cancer	2.63e-05	8.75e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—liver cancer	2.63e-05	8.75e-05	CbGpPWpGaD
